IMR OpenIR
Current status of anticoagulant treatments and improvements for hemodialysis patients in northern Chinese cities: a five-year comparative study
Alternative TitleCurrent status of anticoagulant treatments and improvements for hemodialysis patients in northern Chinese cities: a five-year comparative study
Huang Qi1; Sun Xuefeng1; Lin Hongli2; Zhang Zhimin3; Hao Lirong4; Yao Li5; Li Jijun6; Zhao Delong1; Wang Yong1; Zhu Hanyu1; Chen Xiangmei1
2014
Source PublicationCHINESE MEDICAL JOURNAL
ISSN0366-6999
Volume127Issue:16Pages:2881-2887
AbstractBackground Anticoagulation treatments are an important aspect of hemodialysis; however, few reports have addressed these treatments. This investigation intends to increase the understanding of the current status and improvements of hemodialysis-related anticoagulation treatments in China.
Other AbstractBackground Anticoagulation treatments are an important aspect of hemodialysis; however, few reports have addressed these treatments. This investigation intends to increase the understanding of the current status and improvements of hemodialysis-related anticoagulation treatments in China. Methods In this study, an epidemiological investigation was conducted that examined 842 patients in 2007 and 1 175 patients in 2012 who underwent hemodialysis anticoagulation treatments in seven blood purification centers in northern Chinese cities. Results Heparin was the most commonly used anticoagulant, although the percentage of use of low-molecular-weight heparin (LMWH) increased from 26.5% in 2007 to 42.1% in 2012. In 2007, there were no significant differences in anticoagulant selection among either patients with various primary diseases or patients with hemorrhage, thrombosis, thrombocytopenia, or a low hemoglobin level. However, compared with patients with other diseases, significantly lower doses of LMWH were administered to patients with hypertension (55.5 U/kg vs. 67.3 U/kg, P <0.05) or diabetes (58.5 U/kg vs. 67.3 U/kg, P <0.05), and patients with hemorrhage received lower doses of heparin than the other patients (61.6 U/kg vs. 71.8 U/kg, P <0.01). In 2012, patients with diabetic nephropathy (51.5% vs. 36.5%, P <0.01), hemorrhage (43.4% vs. 31.7%, P <0.01), or a hemoglobin level below 90 g/L (57.2% vs. 37.1%, P <0.01) experienced significantly higher doses of LMWH administration; patients with hemorrhage received significantly reduced LMWH dosages (50.4 U/kg vs. 57.8 U/kg, P <0.05), and patients with thrombosis received significantly higher doses of heparin (73.8 U/kg vs. 62.1 U/kg, P <0.01) or LMWH (57.8 U/kg vs. 52.6 U/kg, P <0.05). Antiplatelet drugs were administered to 20.4% of the examined patients in 2007 and 20.7% in 2012. In 2012, patients with hypertension (25.9% vs. 18.5%, P <0.01) and thrombosis (36.6% vs. 16.1%, P <0.01) had a higher rate of using antiplatelet drugs than patients with other primary diseases and complications. Patients receiving antiplatelet drugs also received higher doses of heparin than patients without using antiplatelet drugs (74.4 U/kg vs. 65.9 U/kg, P <0.01). However, the use of the drugs was not correlated with thrombocytopenia. The rate at which coagulation indices were determined increased from 45.7% in 2007 to 64% in 2012. Conclusion These findings suggested that hemodialysis-related anticoagulation treatments in China have gradually become more standardized and individualized.
KeywordHEPARIN ASPIRIN DISEASE DOPPS hemodialysis heparin low-molecular-weight heparin anticoagulant
Indexed ByCSCD
Language英语
Funding Project[Major State Basic Research Development Program of China] ; [National Natural Science Foundation of China] ; [National Key Technology RD Program] ; [Health Industry Scientific Research Special Project]
CSCD IDCSCD:5214081
Citation statistics
Document Type期刊论文
Identifierhttp://ir.imr.ac.cn/handle/321006/151326
Collection中国科学院金属研究所
Affiliation1.中国人民解放军总医院
2.First Affiliated Hosp, Dalian Med Coll, Department Nephrol, Dalian 116023, Liaoning, Peoples R China
3.Gen Hosp Gen Headquarters, Department Nephrol, Beijing 100091, Peoples R China
4.First Affiliated Hosp, Harbin Med Coll, Department Nephrol, Harbin 150081, Heilongjiang, Peoples R China
5.中国科学院金属研究所
6.Gen Hosp Peoples Liberat Army, Affiliated Hosp 1, Department Nephrol, Beijing 100048, Peoples R China
Recommended Citation
GB/T 7714
Huang Qi,Sun Xuefeng,Lin Hongli,et al. Current status of anticoagulant treatments and improvements for hemodialysis patients in northern Chinese cities: a five-year comparative study[J]. CHINESE MEDICAL JOURNAL,2014,127(16):2881-2887.
APA Huang Qi.,Sun Xuefeng.,Lin Hongli.,Zhang Zhimin.,Hao Lirong.,...&Chen Xiangmei.(2014).Current status of anticoagulant treatments and improvements for hemodialysis patients in northern Chinese cities: a five-year comparative study.CHINESE MEDICAL JOURNAL,127(16),2881-2887.
MLA Huang Qi,et al."Current status of anticoagulant treatments and improvements for hemodialysis patients in northern Chinese cities: a five-year comparative study".CHINESE MEDICAL JOURNAL 127.16(2014):2881-2887.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[Huang Qi]'s Articles
[Sun Xuefeng]'s Articles
[Lin Hongli]'s Articles
Baidu academic
Similar articles in Baidu academic
[Huang Qi]'s Articles
[Sun Xuefeng]'s Articles
[Lin Hongli]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Huang Qi]'s Articles
[Sun Xuefeng]'s Articles
[Lin Hongli]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.